Stocks
Invest in Stocks
Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.
F&O
Create Stock SIPAutomate your investments in this
Performance
Open
101.20Prev. Close
102.22Volume
19,844Total traded value
0.20 CrUpper Circuit
122.66Lower Circuit
81.77Fundamentals
| Market Cap | ₹751Cr |
| ROE | 3.14% |
| P/E Ratio(TTM) | 3.32 |
| EPS(TTM) | 30.75 |
| P/B Ratio | 0.60 |
| Dividend Yield | 0.00% |
| Industry P/E | 34.63 |
| Book Value | 169.62 |
| Debt to Equity | 0.03 |
| Face Value | 10 |
Understand Fundamentals
Financials
About Ind Swift Laboratories
Ind-Swift Laboratories, a prominent global pharmaceutical brand, has strategically decided to enter the business of finished medicines, also known as formulations. This strategic shift is driven by the single objective of unlocking value and strengthening its capacity for future growth and innovation. The company demonstrates a strong global reach, as more than 70% of its revenue was generated from exports to international markets.;
| Parent Organisation | Ind Swift Laboratories |
| Managing Director | Shri. Navrattan Munjal |
| NSE Symbol | INDSWFTLAB |
Shareholding Pattern
Mar '25
Jun '25
Jul '25
Aug '25
Sep '25
Similar Stocks
| COMPANY | 52 WEEK | MARKET PRICE | P/E Ratio | |
|---|---|---|---|---|
| Cohance Lifesciences | NA (0.00%) | 86.40 | ||
| JB Chemicals & Pharmaceuticals | NA (0.00%) | 39.18 | ||
| Emcure Pharmaceuticals | NA (0.00%) | 32.65 | ||
| Wockhardt | NA (0.00%) | -450.62 |